Cargando…
Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
Anti-tumor necrosis factor agents are widely used in treating ankylosing spondylitis, but they increase the risk of infection by suppressing the immune response. Therefore, physicians should be careful about recurrent infections in patients under anti-tumor necrosis factor agents.
Autores principales: | Vural, Sevilay, Kuşdoğan, Mikail, Kaya, Hasan Burak, İkiz, Venhar, Albayrak, Levent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235369/ https://www.ncbi.nlm.nih.gov/pubmed/37274971 http://dx.doi.org/10.1007/s12070-022-03203-0 |
Ejemplares similares
-
Adalimumab (Humira™) in Ophthalmology: A Review of the Literature
por: Neri, Piergiorgio, et al.
Publicado: (2010) -
Adalimumab (Humira) induced acute lung injury
por: Kohli, Ritesh, et al.
Publicado: (2013) -
Peritonsillar Abscess
por: Roy, Dunbar
Publicado: (1898) -
Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015) -
Recurrent Peritonsillar Abscess in Post-tonsillectomy Patient
por: Mirza, Jacqueline, et al.
Publicado: (2022)